Bryostatin 1 induces productive Epstein-Barr virus replication in latently infected cells: implications for use in immunocompromised patients

James P. Stewart, Alan T. McGown, Joseph Prendiville, George Pettit, Brian W. Fox, John R. Arrand

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Bryostatin 1 is a novel anti-tumor agent currently undergoing clinical trial. We investigated the effect of this drug on B-lymphocyte cell lines that carry the Epstein-Barr virus and found that it induces these latently infected cells into the production of transforming virus particles over a wide range of concentrations. These results may have clinical implications, particularly with regard to the use of the drug in the immunocompromised patient.

Original languageEnglish (US)
Pages (from-to)89-91
Number of pages3
JournalCancer Chemotherapy and Pharmacology
Volume33
Issue number1
DOIs
StatePublished - Jan 1993

Fingerprint

Immunocompromised Host
Virus Replication
Human Herpesvirus 4
Viruses
Lymphocytes
Pharmaceutical Preparations
Virion
Tumors
B-Lymphocytes
Cells
Clinical Trials
Cell Line
Neoplasms
bryostatin 1

ASJC Scopus subject areas

  • Pharmacology
  • Oncology
  • Cancer Research

Cite this

Bryostatin 1 induces productive Epstein-Barr virus replication in latently infected cells : implications for use in immunocompromised patients. / Stewart, James P.; McGown, Alan T.; Prendiville, Joseph; Pettit, George; Fox, Brian W.; Arrand, John R.

In: Cancer Chemotherapy and Pharmacology, Vol. 33, No. 1, 01.1993, p. 89-91.

Research output: Contribution to journalArticle

Stewart, James P. ; McGown, Alan T. ; Prendiville, Joseph ; Pettit, George ; Fox, Brian W. ; Arrand, John R. / Bryostatin 1 induces productive Epstein-Barr virus replication in latently infected cells : implications for use in immunocompromised patients. In: Cancer Chemotherapy and Pharmacology. 1993 ; Vol. 33, No. 1. pp. 89-91.
@article{5b8ed13685144d38a9cfece0ff88610b,
title = "Bryostatin 1 induces productive Epstein-Barr virus replication in latently infected cells: implications for use in immunocompromised patients",
abstract = "Bryostatin 1 is a novel anti-tumor agent currently undergoing clinical trial. We investigated the effect of this drug on B-lymphocyte cell lines that carry the Epstein-Barr virus and found that it induces these latently infected cells into the production of transforming virus particles over a wide range of concentrations. These results may have clinical implications, particularly with regard to the use of the drug in the immunocompromised patient.",
author = "Stewart, {James P.} and McGown, {Alan T.} and Joseph Prendiville and George Pettit and Fox, {Brian W.} and Arrand, {John R.}",
year = "1993",
month = "1",
doi = "10.1007/BF00686030",
language = "English (US)",
volume = "33",
pages = "89--91",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Bryostatin 1 induces productive Epstein-Barr virus replication in latently infected cells

T2 - implications for use in immunocompromised patients

AU - Stewart, James P.

AU - McGown, Alan T.

AU - Prendiville, Joseph

AU - Pettit, George

AU - Fox, Brian W.

AU - Arrand, John R.

PY - 1993/1

Y1 - 1993/1

N2 - Bryostatin 1 is a novel anti-tumor agent currently undergoing clinical trial. We investigated the effect of this drug on B-lymphocyte cell lines that carry the Epstein-Barr virus and found that it induces these latently infected cells into the production of transforming virus particles over a wide range of concentrations. These results may have clinical implications, particularly with regard to the use of the drug in the immunocompromised patient.

AB - Bryostatin 1 is a novel anti-tumor agent currently undergoing clinical trial. We investigated the effect of this drug on B-lymphocyte cell lines that carry the Epstein-Barr virus and found that it induces these latently infected cells into the production of transforming virus particles over a wide range of concentrations. These results may have clinical implications, particularly with regard to the use of the drug in the immunocompromised patient.

UR - http://www.scopus.com/inward/record.url?scp=0027482707&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027482707&partnerID=8YFLogxK

U2 - 10.1007/BF00686030

DO - 10.1007/BF00686030

M3 - Article

C2 - 8269596

AN - SCOPUS:0027482707

VL - 33

SP - 89

EP - 91

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 1

ER -